[Featured Stock] Green Cross LabCell Rises on Positive Technology Export News
[Asia Economy Reporter Park So-yeon] Green Cross LabCell is showing strong performance on the back of a technology export deal worth over 2 trillion won.
As of 9:28 AM on the 29th, Green Cross LabCell is trading at 141,000 won, up 20,100 won (16.75%) from the previous day.
On this day, Green Cross LabCell announced that it signed a contract to jointly develop three types of solid cancer-targeting CAR-NK cell therapies worth a total of over 2 trillion won with its U.S. affiliate, Ativa Biotherapeutics.
Hot Picks Today
"Buy on Black Monday"... Japan's Nomura Forecasts 590,000 for Samsung, 4 Million for SK hynix
- "Plunged During the War, Now Surging Again"... The Real Reason Behind the 6% One-Day Silver Market Rally [Weekend Money]
- "We're Now Earning 10 Million Won a Month"... Semiconductor Boom Drives Performance Bonuses at Major Electronic Component Firms
- Trump Warns Iran: "Nothing Will Be Left If They Don't Act Quickly"
- Experts Are Already Watching Closely..."Target Stock Price 970,000 Won" Now Only the Uptrend Remains [Weekend Money]
This contract was signed because Ativa won a joint research and development order from the U.S. MSD (Merck Sharp & Dohme Corp.), and Green Cross LabCell, which holds the original technology, will be responsible for the work.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
